Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2008 Nov;165(11):1442-8.
doi: 10.1176/appi.ajp.2008.08020304. Epub 2008 Sep 2.
Affiliations
- PMID: 18765480
- DOI: 10.1176/appi.ajp.2008.08020304
Randomized Controlled Trial
Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial
Nitya Jayaram-Lindström et al. Am J Psychiatry. 2008 Nov.
Abstract
Objective: Currently there is no approved pharmacotherapy for amphetamine dependence. Recent human laboratory studies have demonstrated that naltrexone modulates some of the reinforcing effects of amphetamine. The aim of this study was to investigate the efficacy of naltrexone in comparison with placebo in reducing relapse to amphetamine use in amphetamine-dependent patients.
Method: Eighty patients who met DSM-IV criteria for amphetamine dependence were randomized to 12 weeks of double-blind naltrexone (50 mg) or placebo treatment. Patients visited the clinic twice weekly to receive medication and relapse prevention therapy and leave urine samples, which were analyzed for drug toxicology and for assessing adherence to medication via detection of naltrexone's metabolite (6-beta-naltrexol). The main outcome measure was abstinence from amphetamine use, as indicated by the total number of negative amphetamine urine samples during 12 weeks of treatment. All missing urine samples were defined for the analysis as positive for amphetamine.
Results: Overall, 55 patients (68.8%) completed the trial. The intention-to-treat analysis showed that the naltrexone group had a significantly higher number of amphetamine-negative urine samples compared with the placebo group. Survival analyses showed that the treatment groups differed in rate of continuous abstinence, in both the intention-to-treat and completer samples, in favor of naltrexone treatment. There was a significant reduction in craving levels and self-reported consumption of amphetamine in the naltrexone group compared with the placebo group. Treatment with naltrexone was well tolerated in this sample.
Conclusions: This trial demonstrated the efficacy of naltrexone in reducing amphetamine use in amphetamine-dependent individuals.
Similar articles
- An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability.
Jayaram-Lindström N, Wennberg P, Beck O, Franck J. Jayaram-Lindström N, et al. Nord J Psychiatry. 2005;59(3):167-71. doi: 10.1080/08039480510023052. Nord J Psychiatry. 2005. PMID: 16195116 Clinical Trial. - Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Krupitsky E, et al. Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9. Lancet. 2011. PMID: 21529928 Clinical Trial. - Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial.
Tiihonen J, Krupitsky E, Verbitskaya E, Blokhina E, Mamontova O, Föhr J, Tuomola P, Kuoppasalmi K, Kiviniemi V, Zwartau E. Tiihonen J, et al. Am J Psychiatry. 2012 May;169(5):531-6. doi: 10.1176/appi.ajp.2011.11071121. Am J Psychiatry. 2012. PMID: 22764364 Clinical Trial. - The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA. Pettinati HM, et al. J Clin Psychopharmacol. 2006 Dec;26(6):610-25. doi: 10.1097/01.jcp.0000245566.52401.20. J Clin Psychopharmacol. 2006. PMID: 17110818 Review. - Do manualized psychosocial interventions help reduce relapse among alcohol-dependent adults treated with naltrexone or placebo? A meta-analysis.
Agosti V, Nunes EV, O'Shea D. Agosti V, et al. Am J Addict. 2012 Nov-Dec;21(6):501-7. doi: 10.1111/j.1521-0391.2012.00270.x. Epub 2012 Sep 21. Am J Addict. 2012. PMID: 23082827 Review.
Cited by
- The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects.
Jones JD, Mumtaz M, Vadhan NP, Martinez S, Pramanik S, Manubay J, Mogali S, Perez F, Castillo F, Kranzler HR, Comer SD. Jones JD, et al. Behav Pharmacol. 2022 Jun 1;33(4):255-265. doi: 10.1097/FBP.0000000000000671. Epub 2022 Apr 12. Behav Pharmacol. 2022. PMID: 35438671 Free PMC article. Clinical Trial. - Pharmacotherapy treatment of stimulant use disorder.
Liu MT. Liu MT. Ment Health Clin. 2021 Nov 8;11(6):347-357. doi: 10.9740/mhc.2021.11.347. eCollection 2021 Nov. Ment Health Clin. 2021. PMID: 34824959 Free PMC article. - Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men.
Santos GM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Hahn JA, Vlahov D, Vittinghoff E, Batki SL. Santos GM, et al. J Acquir Immune Defic Syndr. 2016 May 1;72(1):21-30. doi: 10.1097/QAI.0000000000000922. J Acquir Immune Defic Syndr. 2016. PMID: 26674372 Free PMC article. Clinical Trial. - Neural and psychological mechanisms underlying compulsive drug seeking habits and drug memories--indications for novel treatments of addiction.
Everitt BJ. Everitt BJ. Eur J Neurosci. 2014 Jul;40(1):2163-82. doi: 10.1111/ejn.12644. Epub 2014 Jun 17. Eur J Neurosci. 2014. PMID: 24935353 Free PMC article. Review. - Medications for substance use disorders (SUD): emerging approaches.
Butelman ER, Kreek MJ. Butelman ER, et al. Expert Opin Emerg Drugs. 2017 Dec;22(4):301-315. doi: 10.1080/14728214.2017.1395855. Epub 2017 Oct 30. Expert Opin Emerg Drugs. 2017. PMID: 29057665 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous